Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 44, 2013, Pages 17838-17843

  Wood, Jeremy P ^a   Bunce, Matthew W ^b   Maroney, Susan A ^a   Tracy, Paula B ^c   Camire, Rodney M ^b,d   Mast, Alan E ^a,e  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; FUCOIDIN; HEPARIN; POLYPHOSPHATE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BLEEDING; HEMOPHILIA; THROMBOSIS;

AMINO ACID SEQUENCE; BASE SEQUENCE; BLOOD COAGULATION; BLOTTING, WESTERN; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FLUORESCENCE POLARIZATION; HUMANS; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; THROMBOPLASTIN;

EID: 84887103363     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310444110     Document Type: Article

References (51)

1. Miletich JP, Kane WH, Hofmann SL, Stanford N, Majerus PW (1979) Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood 54(5):1015-1022.
2. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S (1990) Surfacedependent reactions of the vitamin K-dependent enzyme complexes. Blood 76(1):1-16.
3. Lawson JH, Kalafatis M, Stram S, Mann KG (1994) A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269(37):23357-23366.
4. Monkovic DD, Tracy PB (1990) Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem265(28):17132-17140.
5. Viskup RW, Tracy PB, Mann KG (1987) The isolation of human platelet factor V. Blood 69(4):1188-1195.
6. Maroney SA, Ellery PE, Mast AE (2010) Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res 125(Suppl 1):S52-S56.
7. Girard TJ, et al. (1989) Functional significance of the Kunitz-Type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338(6215):518-520.
8. Baugh RJ, Broze GJ, Jr., Krishnaswamy S (1998) Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 273(8):4378-4386.
9. Hackeng TM, Seré KM, Tans G, Rosing J (2006) Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103(9):3106-3111.
10. Ndonwi M, Tuley EA, Broze GJ, Jr. (2010) The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 116(8): 1344-1351.
11. Maroney SA, et al. (2007) Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 109(5):1931-1937.
12. Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr. (1988) Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72(6):2020-2025.
13. Hansen JB, et al. (2000) Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 83(6):937-943.
14. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF (1995) Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 15(11): 2055-2062.
15. Lupu C, et al. (1999) Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 19(9):2251-2262.
16. Maroney SA, et al. (2013) Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI) and TFPI. J Thromb Haemost 11(5):911-918.
17. Franssen J, et al. (1997) Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: Competition between prothrombin and inhibitor. Biochem J 323(Pt 1):33-37.
18. Mast AE, Broze GJ, Jr. (1996) Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 87(5):1845-1850.
19. Han X, Fiehler R, Broze GJ, Jr. (2000) Characterization of the protein Z-dependent protease inhibitor. Blood 96(9):3049-3055.
20. Brufatto N, Ward A, Nesheim ME (2003) Factor Xa is highly protected from antithrombin- fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 1(6):1258-1263.
21. Tran S, Norstrom E, Dahlbäck B (2008) Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 283(11): 6648-6655.
22. Orfeo T, Brummel-Ziedins KE, Gissel M, Butenas S, Mann KG (2008) The nature of the stable blood clot procoagulant activities. J Biol Chem 283(15):9776-9786.
23. Girard TJ, Tuley E, Broze GJ, Jr. (2012) TFPI is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood 119(5):1256-1262.
24. Maroney SA, et al. (2009) Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost 7(7):1106-1113.
25. Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Mast AE (2011) Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol 31(4):821-826.
26. Maroney SA, et al. (2012) Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 109(10): 3927-3931.
27. Massberg S, et al. (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16(8):887-896.
28. Bos MH, Camire RM (2012) A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem 287(31):26342-26351.
29. Zhu H, Toso R, Camire RM (2007) Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state. J Biol Chem 282(20):15033-15039.
30. Ndonwi M, Girard TJ, Broze GJ, Jr. (2012) The carboxy-Terminus of TFPIalpha is required for its interaction with factor V and Va. J Thromb Haemost 10(9):1944-1946.
31. Monkovic DD, Tracy PB (1990) Activation of human factor V by factor Xa and thrombin. Biochemistry 29(5):1118-1128.
32. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ, Jr. (1991) Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78(2):387-393.
33. Broze GJ, Jr., Lange GW, Duffin KL, MacPhail L (1994) Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5(4):551-559.
34. Liu T, et al. (2006) Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 95(1):68-76.
35. Smith SA, et al. (2010) Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116(20):4353-4359.
36. Smith SA, Morrissey JH (2008) Heparin is procoagulant in the absence of antithrombin. Thromb Haemost 100(1):160-162.
37. Smith SA, et al. (2006) Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 103(4):903-908.
38. Schuijt TJ, et al. (2013) Factor xa activation of factor v is of paramount importance in initiating the coagulation system: Lessons from a tick salivary protein. Circulation 128(3):254-266.
39. Vincent LM, et al. (2013) Coagulation factor VA2440G causes east Texas bleeding disorder via TFPI. J Clin Invest 123(9):3777-3787.
40. Lechtenberg BC, et al. (2013) Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Blood, 10.1182/blood-2013-06- 511733.
41. Prasad S, et al. (2008) Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111(2):672-679.
42. Semeraro F, et al. (2011) Extracellular histones promote thrombin generation through platelet-dependent mechanisms: Involvement of platelet TLR2 and TLR4. Blood 118(7):1952-1961.
43. Ruiz FA, Lea CR, Oldfield E, Docampo R (2004) Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 279(43):44250-44257.
44. Wencel-Drake JD, Dahlback B, White JG, Ginsberg MH (1986) Ultrastructural localization of coagulation factor V in human platelets. Blood 68(1):244-249.
45. Gorczyca ME, et al. (2012) Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost 10(8): 1581-1590.
46. Hilden I, et al. (2012) Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 119(24): 5871-5878.
47. Knappe S, et al. (2013) Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood. Thromb Haemost 109(3):450-457.
48. Betz A, Krishnaswamy S (1998) Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem 273(17):10709-10718.
49. Buddai SK, Toulokhonova L, Bergum PW, Vlasuk GP, Krishnaswamy S (2002) Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem 277(29): 26689-26698.
50. Wood JP, Silveira JR, Maille NM, Haynes LM, Tracy PB (2011) Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity. Blood 117(5):1710-1718.
51. Larkin MA, et al. (2007) Clustal W and Clustal X Version 2.0. Bioinformatics 23(21): 2947-2948.